BRPI0416740A - interação de receptor de nmda com a proteìna tirosina fosfatase step em distúrbios psicóticos - Google Patents

interação de receptor de nmda com a proteìna tirosina fosfatase step em distúrbios psicóticos

Info

Publication number
BRPI0416740A
BRPI0416740A BRPI0416740-6A BRPI0416740A BRPI0416740A BR PI0416740 A BRPI0416740 A BR PI0416740A BR PI0416740 A BRPI0416740 A BR PI0416740A BR PI0416740 A BRPI0416740 A BR PI0416740A
Authority
BR
Brazil
Prior art keywords
nmda receptor
protein tyrosine
tyrosine phosphatase
receptor interaction
psychotic disorders
Prior art date
Application number
BRPI0416740-6A
Other languages
English (en)
Inventor
Steven Braithwaite
Jasna Jerecic
Roman Urfer
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0416740A publication Critical patent/BRPI0416740A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"INTERAçãO DE RECEPTOR DE NMDA COM A PROTEìNA TIROSINA FOSFATASE STEP EM DISTúRBIOS PSICóTICOS". A presente invenção refere-se à identificação de STEP conforme envolvida em cursos de sinalização relacionados a doenças psicóticas incluindo esquizofrenia e outros distúrbios onde disfunção do receptor de NMDA está implicada. A presente invenção provê métodos para avaliação de inibidores de STEP que modulam a sinalização de NMDA-R. A presente invenção também provê métodos e composições para o tratamento de distúrbios mediados por sinalização de NMDA-R anormal.
BRPI0416740-6A 2003-12-08 2004-12-08 interação de receptor de nmda com a proteìna tirosina fosfatase step em distúrbios psicóticos BRPI0416740A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52818203P 2003-12-08 2003-12-08
PCT/US2004/041289 WO2005055813A2 (en) 2003-12-08 2004-12-08 Interaction of nmda receptor with the protein tyrosine phosphatase step in psychotic disorders

Publications (1)

Publication Number Publication Date
BRPI0416740A true BRPI0416740A (pt) 2007-01-16

Family

ID=34676826

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416740-6A BRPI0416740A (pt) 2003-12-08 2004-12-08 interação de receptor de nmda com a proteìna tirosina fosfatase step em distúrbios psicóticos

Country Status (5)

Country Link
US (1) US20050142630A1 (pt)
EP (1) EP1702077A4 (pt)
BR (1) BRPI0416740A (pt)
CA (1) CA2548495A1 (pt)
WO (1) WO2005055813A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005053947A1 (de) * 2005-11-11 2007-05-16 Univ Ernst Moritz Arndt Neue Arzneimittel
GB0701096D0 (en) * 2007-01-19 2007-02-28 Glaxo Group Ltd Use
AR079814A1 (es) * 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
CA2811086C (en) 2010-09-15 2020-07-21 Stc.Unm Step-derived peptide for brain injury treatment
US20230130579A1 (en) * 2020-01-31 2023-04-27 Unm Rainforest Innovations Regulation of post-ischemic inflammatory response: a novel function of tyrosine phosphatase step

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56144237A (en) * 1980-04-07 1981-11-10 Teijin Ltd Polyester type fiber woven and knitted fabric
JPS59192709A (ja) * 1983-04-15 1984-11-01 Toray Ind Inc 太細を有し、表面に溝のある繊維及びその製造方法
CA2398250A1 (en) * 2000-02-01 2001-08-09 Agy Therapeutics, Inc. Interaction of nmda receptor with protein tyrosine phosphatase
JP2004513620A (ja) * 2000-06-16 2004-05-13 インサイト・ゲノミックス・インコーポレイテッド プロテインホスファターゼ

Also Published As

Publication number Publication date
WO2005055813A2 (en) 2005-06-23
US20050142630A1 (en) 2005-06-30
EP1702077A2 (en) 2006-09-20
WO2005055813A3 (en) 2005-09-29
EP1702077A4 (en) 2007-10-31
CA2548495A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
FR21C1031I2 (fr) Derives de la n4-phenyl-quinazoline-4-amine et composes similaires en tant que inhibiteurs de la kinase tyrosine erbb type i pour le traitement de maladies hyperproliferatives
BR0316606A (pt) Derivados de aminoindazóis e sua utilização como inibidores de quinases
MA58373B1 (fr) Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
MA28909B1 (fr) Quinazolines utiles en tant que modulateurs de canaux ioniques
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
BRPI0407454A (pt) Pirazóis e métodos de preparar e usar os mesmos
BRPI0409173A (pt) compostos e composições como inibidores de proteìna quinase
MA31153B1 (fr) Composés et méthodes pour moduler une kinase et indications associées
SI1660507T1 (sl) Proteasomski inhibitorji in metode uporabe le-teh
BRPI0414930A (pt) compostos e composições como inibidores de proteìnas cinases
EP2096919A4 (en) SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] CHINAZOLINE DERIVATIVES SUITABLE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDER AND ANGIOGENIC RELATED DISEASES
PT1199069E (pt) Utilização de um agonista/antagonista de estrogénio para melhoramento ou manutenção da saúde urogenital
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
NO20035474D0 (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
BRPI0417732A (pt) aplicação de gene amilóide a sérico no diagnóstico e tratamento do glaucoma e identificação de agentes antiglaucoma
Devader et al. In vitro and in vivo regulation of synaptogenesis by the novel antidepressant spadin
ATE394124T1 (de) Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums
Ris et al. Sexual dimorphisms in the effect of low‐level p25 expression on synaptic plasticity and memory
MA30775B1 (fr) Inhibiteur du recepteur plaquettaire de l'adp
ATE505192T1 (de) Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit- protein
Caudle et al. GR89, 696 is a kappa-2 opioid receptor agonist and a kappa-1 opioid receptor antagonist in the guinea pig hippocampus

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]